Valuation: Realcan Pharmaceutical Group Co., Ltd.

Market Cap 5.26B 781M 674M 632M 576M 1.08B 74.65B 1.1B 7.41B 2.9B 37.4B 2.93B 2.87B 124B P/E 2024
217x
P/E 2025 322x
Enterprise Value 6.12B 908M 784M 736M 670M 1.26B 86.85B 1.28B 8.62B 3.38B 43.51B 3.41B 3.34B 145B EV / Sales 2024
0.76x
EV / Sales 2025 0.77x
Free-Float
69.07%
Yield 2024
0.37%
Yield 2025 0.06%
05-19 Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for 2025 for A shares, Payable on 30 June 2026 CI
04-24 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. announces Annual dividend, payable on June 30, 2026 CI
04-22 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-07 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
11-06 Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on November 11, 2024, has closed with 34,638,659 shares, representing 2.31% for CNY 101.48 million. CI
29/10/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
13/10/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
25/08/25 Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 CI
03/07/25 Realcan Pharmaceutical Vice President Detained MT
02/07/25 Tranche Update on Realcan Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on November 11, 2024. CI
03/06/25 Yanquan No. 8 Private Securities Investment Fund, a fund managed by Jiaxing Yanquan Investment Partnership LLP cancelled the acquisition of 5.05% stake in Realcan Pharmaceutical Group Co., Ltd. from Zhang Renhua for approximately CNY 160 million. CI
03/06/25 Realcan Pharmaceutical Group Shareholder Nixes Share Transfer Deal MT
1 day+1.42%
1 week+17.76%
Current month+30.18%
1 month+25.61%
3 months+18.15%
6 months+9.48%
Current year+11.18%
1 week 3.15
Extreme 3.15
3.9
1 month 2.59
Extreme 2.59
3.9
Current year 2.38
Extreme 2.38
4.11
1 year 2.38
Extreme 2.38
4.69
3 years 2.05
Extreme 2.05
4.69
5 years 2.05
Extreme 2.05
6.73
10 years 2.05
Extreme 2.05
18.26
Manager TitleAgeSince
Director of Finance/CFO 56 25/04/2021
President 61 25/05/2023
Corporate Officer/Principal 40 29/10/2019
Director TitleAgeSince
Chairman 61 20/11/2009
Director/Board Member 43 20/11/2009
Chairman 48 07/10/2019
Date Insider Type Main position Quantity % Market Cap.
12/05/23 Sell

Founder

15,000,000 1.2902%
30/03/23 Sell

Founder

13,040,000 1.1260%
30/03/23 Sell

Chairman

2,000,000 0.1727%
Change 5-day change 1-year change 3-year change Capi.($)
+1.42%+17.76%+20.13%-3.76% 769M
-0.08%-1.46%+29.18%+107.95% 101B
+0.43%-0.42%+57.74%+173.39% 54.69B
-1.01%-1.01%+3.87%+278.21% 24.3B
-0.72%-1.38%-12.44%-16.10% 8.24B
-0.94%+1.55%-31.55%-24.78% 7.73B
+0.60%-0.94%-14.15%-22.40% 6.64B
+1.46%+3.75%+11.82%+18.78% 6.33B
-0.18%-1.52%-3.52%+15.56% 4.98B
-1.38%0.00%-6.55%-8.69% 3.74B
Average -0.07%+0.55%+5.45%+51.82% 21.87B
Weighted average by Cap. -0.06%-0.26%+26.59%+122.84%

Financials

2024 2025
Net sales 7.97B 1.18B 1.02B 957M 872M 1.64B 113B 1.66B 11.22B 4.4B 56.61B 4.44B 4.34B 188B 7.3B 1.08B 934M 877M 798M 1.5B 103B 1.52B 10.28B 4.03B 51.84B 4.06B 3.98B 172B
Net income 20.62M 3.06M 2.64M 2.48M 2.26M 4.24M 292M 4.3M 29.04M 11.38M 147M 11.49M 11.24M 487M 16.07M 2.38M 2.06M 1.93M 1.76M 3.31M 228M 3.35M 22.64M 8.87M 114M 8.95M 8.76M 380M
Net Debt 1.6B 237M 204M 192M 175M 328M 22.63B 333M 2.25B 880M 11.34B 889M 869M 37.71B 860M 128M 110M 103M 94.14M 177M 12.2B 179M 1.21B 475M 6.11B 479M 469M 20.34B
Logo Realcan Pharmaceutical Group Co., Ltd.
Realcan Pharmaceutical Group Co Ltd, formerly Realcan Pharmaceutical Co Ltd, is a China-based company mainly engaged in the provision of comprehensive medical service. The Company operates five businesses. The drug and device distribution business is mainly responsible for drug and device distribution services and comprehensive medical services. The in vitro diagnostic business covers all fields such as laboratory biochemistry, immunity, and clinical examination. The digital health business provides one-stop health management solutions. The pharmaceutical logistics business provides pharmaceutical and medical device logistics services. The traditional Chinese medicine business is engaged in the research, development and production of traditional Chinese medicine pieces, granules, new traditional Chinese medicines, liquefied traditional Chinese medicine products, and health foods. The Company mainly operates in the domestic market, with Shandong as its main market.
Employees
2,407
Date Price Change Volume
16/08/26 CN¥3.580 +1.42% 296,818,500
14/08/26 CN¥3.530 -4.85% 254,799,542
13/08/26 CN¥3.710 +4.51% 393,381,828
12/08/26 CN¥3.550 +9.91% 244,065,297
11/08/26 CN¥3.230 -3.29% 248,277,818
  1. Stock Market
  2. Stocks
  3. 002589 Stock